Combination therapy for high-risk or borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of three drugs—surufatinib, chemotherapy (mFOLFIRINOX), and an immunotherapy (PD-1 inhibitor)—given before surgery to shrink tumors and improve outcomes for people with pancreatic cancer that is high-risk or borderline resectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic cancer that is high-risk (e.g., large tumor, high CA 19-9 level) or borderline resectable (tumor touching key blood vessels but still potentially removable).
- You have not had any previous chemotherapy, radiation, or surgery for this cancer.
- You do not have BRCA1/2 or PALB2 gene mutations.
- You have good overall health (ECOG score 0 or 1) and adequate organ function (kidney, liver, blood counts).
- You are willing to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—surufatinib (a targeted therapy), camrelizumab (an immunotherapy), and a chemotherapy regimen called mFOLFOX6—as a second-line treatment for advanced pancreatic cancer. It's for people whose cancer progressed after first-line gemcitabine-based chemotherapy.
This trial tests if adding two targeted drugs (surufatinib and serplulimab) to standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. It may help people whose cancer hasn't spread and who haven't had prior treatment.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.